Impact of Mirabegron on Erectile Function in BPH Patients

Kasr El Aini Hospital

Status: Unknown

Conditions: Males With Benign Prostatic Hyperplasia Symptoms

Treatments: Drug: Alpha Blockers; Drug: Mirabegron 50 MG

Study type: Observational

Funder types: Other

Identifiers

NCT04503850

Cairo University Hospitals

Details and patient eligibility

About

Evaluation of impact of Mirabegron on erectile function for patients treated for BPH

Full description

50 patients (Group A) will receive Mirabegron & alpha blocker 50 patients (Group B) will receive alpha blocker only Evaluation using IIEF 5 scoring system

Enrollment: 100 estimated patients

Sex: Male

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All males above age 50 with LUTS due to BPH not candidate for prostatectomy

Exclusion criteria

• males below age 50
• neurologic abnormality
• Any indication for prostatectomy
• abnormal bladder contractility i.e diabetics

Trial design

100 participants in 2 patient groups

Group A Mirabegron

Description:

50 patients receiving Mirabegron 50 mg once daily \& alpha blocker

Treatment:

Drug: Mirabegron 50 MG

Group B alpha blocker only

Description:

50 patients receiving alpha blocker only

Treatment:

Drug: Alpha Blockers